Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • FIPB clears 6 FDI...

    FIPB clears 6 FDI proposals worth Rs 1,187 crore

    Written by supriya kashyap kashyap Published On 2017-01-20T09:11:21+05:30  |  Updated On 20 Jan 2017 9:11 AM IST
    FIPB clears 6 FDI proposals worth Rs 1,187 crore

    New Delhi : Inter-ministerial body FIPB approved six investment proposals, including that of Sanofi Synthelabo India, Star Den Media Services and Idea Cellular Infrastructure Services, envisaging foreign investments of Rs 1,186.5 crore.


    Of the total, Recipharm Participation BV of Netherlands alone will bring in investment of Rs 950 crore.


    The company had sought approval for 100 per cent foreign direct investment in a proposed Recipharm Group Indian Investing Company through which it will completely acquire in an existing pharmaceutical manufacturing company Dagny Pharma.


    The Foreign Investment Promotion Board (FIPB), headed by Economic Affairs Secretary Shaktikanta Das also gave nod to the proposals of Boehringer Ingelheim India Pvt Ltd and A Menarini India Pvt Ltd entailing investment of Rs 156.5 crore and Rs 80 crore respectively.


    The panel rejected three proposals, including that of AMP Solar India Pvt Ltd.


    Six proposals were deferred for further consultation and want of more information, sources added.


    Some of the proposals which were deferred were those of Crest Premedia Solutions Pvt Ltd, You Broadband India and Scientific Publishing Services Pvt Ltd.


    India allows FDI in most sectors through the automatic route, but in certain segments considered sensitive for the economy and security, the proposals have to be first cleared by FIPB.


    The government has taken a slew of measures in the recent past to boost foreign direct investment into the country.


    With growth in FDI in important sectors like services and manufacturing, overall foreign inflows in the country rose by 30 per cent to $21.62 billion during the first half of 2016-17.


    During the April-October period of the current fiscal FDI grew by over 27 per cent to $27.82 billion as against $21.87 billion same period a year ago.


    FDI in India grew by 29 per cent to $40 billion in 2015-16 as against $30.94 billion in the previous financial year.

    Boehringer IngelheimDagny PharmaFDIFIPBforeign direct investmentForeign Investment Promotion BoardSanofi
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok